5/17/23 5/17/23

Victoria Donovan Honored as Entrepreneur in Prestigious ELITE 100 Awards

We are thrilled to announce that Clinically Media's CEO, Victoria Donovan, has been recognized and celebrated as an Entrepreneur in this year's esteemed ELITE 100 Awards. This prestigious accolade acknowledges individuals in the healthcare and life sciences industry who are making a lasting impact on patients, colleagues, and the world.

10/18/22 10/18/22

ACRP Published Our Team’s Article on DEI

In the published article, authors, Kate Schroeder and Seth Palmer, explore many solutions to promote DEI in patient recruitment and retention.

9/16/22 9/16/22

PM360 Features Victoria Donovan in Thought Piece on Patient Centricity

PM360 asks Victoria Donovan for her thoughts on patient centricity

7/22/22 7/22/22

Clinically Media Named Top Patient Recruitment Company

Clinically Media was selected by Life Sciences Review's panel of experts as the top company providing patient recruitment solutions.

6/27/22 6/27/22

Clinically Media's CEO Shares Her Vision in an Interview with Shoutout Colorado

Shoutout Colorado interviewed Clinically Media CEO, Victoria Donovan. They talked about what success means, what she wants the world to know about her, and what she hopes to contribute to healthcare.

6/13/22 6/13/22

Q&A with One of the Top 25 Most Influential Young Professionals

Clinically Media’s own CEO, Victoria Donovan, was named one of ColoradoBiz Magazine’s GenXYZ Top 25 Most Influential Young Professionals!

5/23/22 5/23/22

Clinically Media’s CEO Named One Of The Most Influential People in Healthcare Today

Victoria Donovan founded Clinically Media to support sponsors and researchers, in Colorado and nationwide, to advance science and help people everywhere.

4/15/22 4/15/22

Clinically Media Founder Named GenXYZ Top 50 Young Professionals

ColoradoBiz is proud to announce their GenXYZ Top 50 Young Professionals.

3/14/22 3/14/22

PM360 Q&A with Victoria Donovan, Founder and CEO, Clinically Media

Clinical trial operations have experienced some challenges and evolutions as a result of the pandemic. What have been the biggest hurdles with getting patients to join trials during this time?